Effect of high-dose 1.25 dihydroxyvitamin D3 on remyelination in the cuprizone model

APMIS

Volumn 122, Issue 12, 2014, Pages 1178-1186

  Nystad, Agnes E ^a,b   Wergeland, Stig ^a,b   Aksnes, Lage ^a,b   Myhr, Kjell Morten ^a,b   Bø, Lars ^a,b   Torkildsen, Øivind ^a,b  

^a HAUKELAND UNIVERSITY HOSPITAL   (Norway)

^b UNIVERSITY OF BERGEN   (Norway)

Author keywords

Calcitriol; Cuprizone; Multiple sclerosis; Remyelination; Vitamin D

Indexed keywords

CALCITRIOL; CALCIUM; CUPRIZONE; MYELIN; PLACEBO; MYELIN PROTEIN; PROTEIN NOGO;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ASTROCYTE; ASTROCYTOSIS; CALCIUM BLOOD LEVEL; CELL ACTIVATION; CELL DENSITY; CELL INFILTRATION; CONTROLLED STUDY; DEMYELINATION; DIETARY INTAKE; DRUG EFFECT; DRUG MEGADOSE; FEMALE; MACROPHAGE; MICROGLIA; MOUSE; MYELINATION; NONHUMAN; OLIGODENDROGLIA; PRIORITY JOURNAL; REMYELINIZATION; ROTAROD TEST; T LYMPHOCYTE; WEIGHT REDUCTION; ANIMAL; BRAIN; C57BL MOUSE; CHEMICALLY INDUCED; DEMYELINATING DISEASE; DIET SUPPLEMENTATION; DOSE RESPONSE; DRUG EFFECTS; GLIOSIS; METABOLISM; MYELIN SHEATH; PATHOLOGY; TOXICITY;

ANIMALS; BRAIN; CALCITRIOL; CUPRIZONE; DEMYELINATING DISEASES; DIETARY SUPPLEMENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GLIOSIS; MICE; MICE, INBRED C57BL; MYELIN PROTEINS; MYELIN SHEATH; T-LYMPHOCYTES;

EID: 84922480716     PISSN: 09034641     EISSN: 16000463     Source Type: Journal    
DOI: 10.1111/apm.12281     Document Type: Article

References (33)

1. Compston A, Coles A. Multiple sclerosis. Lancet 2008;372:1502-17.
2. Pugliatti M, Casetta I, Drulovic J, Granieri E, Holmoy T, Kampman MT, et al. A questionnaire for multinational case-control studies of environmental risk factors in multiple sclerosis (EnvIMS-Q). Acta Neurol Scand Suppl 2012;195:43-50.
3. Simon KC, Munger KL, Ascherio A. Vitamin D and multiple sclerosis: epidemiology, immunology, and genetics. Curr Opin Neurol 2012;25:246-51.
4. Løken-Amsrud KI, Holmøy T, Bakke SJ, Beiske AG, Bjerve KS, Bjørnara BT, et al. Vitamin D and disease activity in multiple sclerosis before and during interferon-beta treatment. Neurology 2012;79:267-73.
5. Simpson S Jr, Taylor B, Blizzard L, Ponsonby AL, Pittas F, Tremlett H, et al. Higher 25-hydroxyvitamin D is associated with lower relapse risk in multiple sclerosis. Annals of neurology 2010;68:193-203.
6. Myhr KM. Vitamin D treatment in multiple sclerosis. J Neurol Sci 2009;286:104-8.
7. Hewer S, Lucas R, van der Mei I, Taylor BV. Vitamin D and multiple sclerosis. Journal of clinical neuroscience. official journal of the Neurosurgical Society of Australasia. 2013;20:634-41.
8. Soilu-Hanninen M, Aivo J, Lindstrom BM, Elovaara I, Sumelahti ML, Farkkila M, et al. A randomised, double blind, placebo controlled trial with vitamin D3 as an add on treatment to interferon beta-1b in patients with multiple sclerosis. J Neurol Neurosurg Psychiatry 2012;83:565-71.
9. Stein MS, Liu Y, Gray OM, Baker JE, Kolbe SC, Ditchfield MR, et al. A randomized trial of high-dose vitamin D2 in relapsing-remitting multiple sclerosis. Neurology 2011;77:1611-8.
10. Kampman MT, Steffensen LH, Mellgren SI, Jørgensen L. Effect of vitamin D3 supplementation on relapses, disease progression, and measures of function in persons with multiple sclerosis: exploratory outcomes from a double-blind randomised controlled trial. Mult scler 2012;18:1144-51.
11. Benardais K, Kotsiari A, Skuljec J, Koutsoudaki PN, Gudi V, Singh V, et al. Cuprizone [Bis(Cyclohexylidenehydrazide)] is selectively toxic for mature oligodendrocytes. Neurotox Res 2013;24:244-50.
12. Buschmann JP, Berger K, Awad H, Clarner T, Beyer C, Kipp M. Inflammatory response and chemokine expression in the white matter corpus callosum and gray matter cortex region during cuprizone-induced demyelination. Journal of molecular neuroscience: MN 2012;48:66-76.
13. Hiremath MM, Saito Y, Knapp GW, Ting JPY, Suzuki K, Matsushima GK. Microglial/macrophage accumulation during cuprizone-induced demyelination in C57BL/6 mice. J Neuroimmunol 1998;92:38-49.
14. Kipp M, Clarner T, Dang J, Copray S, Beyer C. The cuprizone animal model: new insights into an old story. Acta Neuropathol 2009;118:723-36.
15. Matsushima GK, Morell P. The neurotoxicant, cuprizone, as a model to study demyelination and remyelination in the central nervous system. Brain Pathol 2001;11:107-16.
16. Lindner M, Heine S, Haastert K, Garde N, Fokuhl J, Linsmeier F, et al. Sequential myelin protein expression during remyelination reveals fast and efficient repair after central nervous system demyelination. Neuropathol Appl Neurobiol 2008;34:105-14.
17. Wergeland S, Torkildsen Ø, Myhr KM, Aksnes L, Mørk SJ, Bø L. Dietary vitamin D3 supplements reduce demyelination in the cuprizone model. PLoS ONE. 2011;6:e26262.
18. Holmøy T, Kampman MT, Smolders J. Vitamin D in multiple sclerosis: implications for assessment and treatment. Expert Rev Neurother 2012;12:1101-12.
19. Paxinos GF, Keith B.J. The mouse brain in stereotaxic coordinates. Amsterdam; London: Elsevier Academic Press, 2008.
20. Duchen LW. In: Adams JH CJ, Duchen LWeditors. Greenfield's neuropathology: General pathology of neurons and glia. New York, USA: Wiley, 1984: 1-52.
21. Bruck W, Pfortner R, Pham T, Zhang J, Hayardeny L, Piryatinsky V, et al. Reduced astrocytic NF-kappaB activation by laquinimod protects from cuprizone-induced demyelination. Acta Neuropathol 2012;124:411-24.
22. Aksnes L. Simultaneous determination of retinol, alpha-tocopherol, and 25-hydroxyvitamin D in human serum by high-performance liquid chromatography. J Pediatr Gastroenterol Nutr 1994;18:339-43.
23. Michaylova V, Ilkova P. Photometric determination of micro amounts of calcium with arsenazo III. Anal Chim Acta 1971;53:194-8.
24. Franco-Pons N, Torrente M, Colomina MT, Vilella E. Behavioral deficits in the cuprizone-induced murine model of demyelination/remyelination. Toxicol Lett 2007;169:205-13.
25. Smolders J, Damoiseaux J, Menheere P, Hupperts R. Vitamin D as an immune modulator in multiple sclerosis, a review. J Neuroimmunol 2008;194:7-17.
26. Eyles DW, Smith S, Kinobe R, Hewison M, McGrath JJ. Distribution of the vitamin D receptor and 1 alpha-hydroxylase in human brain. J Chem Neuroanat 2005;29:21-30.
27. Smolders J, Schuurman KG, van Strien ME, Melief J, Hendrickx D, Hol EM, et al. Expression of vitamin D receptor and metabolizing enzymes in multiple sclerosis-affected brain tissue. J Neuropathol Exp Neurol 2013;72:91-105.
28. Streit WJ. Microglia as neuroprotective, immunocompetent cells of the CNS. Glia 2002;40:133-9.
29. Nair A, Frederick TJ, Miller SD. Astrocytes in multiple sclerosis: a product of their environment. Cell Mol Life Sci 2008;65:2702-20.
30. Skripuletz T, Gudi V, Hackstette D, Stangel M. De- and remyelination in the CNS white and grey matter induced by cuprizone: the old, the new, and the unexpected. Histol Histopathol 2011;26:1585-97.
31. Lindner M, Fokuhl J, Linsmeier F, Trebst C, Stangel M. Chronic toxic demyelination in the central nervous system leads to axonal damage despite remyelination. Neurosci Lett 2009;453:120-5.
32. Dorr J, Ohlraun S, Skarabis H, Paul F. Efficacy of Vitamin D supplementation in multiple sclerosis (EVIDIMS Trial): study protocol for a randomized controlled trial. Trials.2012;13:15.
33. Smolders J, Hupperts R, Barkhof F, Grimaldi LME, Holmoy T, Killestein J, et al. Efficacy of vitamin D-3 as add-on therapy in patients with relapsing-remitting multiple sclerosis receiving subcutaneous interferon beta-1a:a Phase II, multicenter, double-blind, randomized, placebo-controlled trial. J Neurol Sci 2011;311:44-9.